Citation

Poklis JL, Nanco CR, Troendle MM, Wolf CE, Poklis A. Drug Test. Anal. 2013; 6(7-8): 764-769.

Affiliation

Departments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA, USA.

Copyright

(Copyright © 2013, John Wiley and Sons)

DOI

10.1002/dta.1522

PMID

24000244

Abstract

We present a case of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe), an N-benzyl phenethylamines derivative, intoxication and a high performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS) method for detection and quantification of 25B-NBOMe. A 19-year-old male was found unresponsive with generalized grand mal seizure activity. On the second day of hospitalization, a friend admitted that the patient used 'some unknown drug' called 25B. Serum and urine collected were sent to the Virginia Commonwealth University Medical Center Toxicology Laboratory for analysis. An HPLC-MS/MS method for the identification and quantification of 25B-NBOMe using 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25H-NBOMe) as the internal standard (ISTD) was developed. As this is a novel, single-case presentation, an assay validation was performed prior to testing to ensure the reliability of the analytical results. The serum and urine specimens were determined to contain 180 pg/ml and1900 pg/ml of 25B-NBOMe, respectively. Copyright © 2013 John Wiley & Sons, Ltd.

Language: en